Cerus Corporation (NASDAQ:CERS) represented a move of 3.25 percent or $-0.17 per share and closed its previous day trading session at $4.13. 910086 Shares were traded in the last trading session with an Average Volume of 1.25 Million Shares. The stock currently has a Market Capitalization of 479.62 Million.
Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company’s initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.
The stock traded between $1.93 and $5.43 over 1-Year time period showing its price to sales ratio of 10.73. Cerus Corporation (NASDAQ:CERS) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $3.67 and 200-Day Simple Moving Average of $34.23. Its Price to Free Cash Flow is 0 and Price to Book of 12.15.
Analyst’s recommended the stock as 1.8 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Cerus Corporation (NASDAQ:CERS) reported its Actual EPS of $-0.12/share. The analysts offering Earnings Estimates for the company were believing that Cerus Corporation could bring EPS of $-0.15/share. The difference between Actual EPS and Estimated EPS was 0.03 Percent. Thus showing an Earnings Surprise of 20 Percent.
Affimed N.V. (NASDAQ:AFMD)
In the last trading session, Affimed N.V. (NASDAQ:AFMD) added its value by 6.1% closing at the price of $2.17. The stock currently has market capitalization of 94.07 Million, with average volume of 767.37 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Affimed N.V. (NASDAQ:AFMD) is showing beta of 0.71. This particular value of beta suggests that Affimed N.V. (NASDAQ:AFMD) has historically moved 71% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Affimed N.V. (NASDAQ:AFMD) is at $-0.87.
The stock currently has RSI of 60.65. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany.
Affimed N.V. (NASDAQ:AFMD) topped its 52-week high price of $2.95 on 03/10/17 and 52-Week Low Price of $1.15 on 12/21/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.44% and monthly volatility of 10.53% respectively.